Founder of EuroEyes International Eye Clinic Jörn Jörgensen Buys More Stock

Even if it's not a huge purchase, we think it was good to see that Jörn Jörgensen, the Founder of EuroEyes International Eye Clinic Limited (HKG:1846) recently shelled out HK$722k to buy stock, at HK$3.34 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The Last 12 Months Of Insider Transactions At EuroEyes International Eye Clinic

Notably, that recent purchase by Jörn Jörgensen is the biggest insider purchase of EuroEyes International Eye Clinic shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being HK$3.28). It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Jörn Jörgensen was the only individual insider to buy during the last year.

Jörn Jörgensen bought 277.00k shares over the last 12 months at an average price of HK$3.62. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for EuroEyes International Eye Clinic

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership Of EuroEyes International Eye Clinic

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. EuroEyes International Eye Clinic insiders own 64% of the company, currently worth about HK$673m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At EuroEyes International Eye Clinic Tell Us?

The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. When combined with notable insider ownership, these factors suggest EuroEyes International Eye Clinic insiders are well aligned, and quite possibly think the share price is too low. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing EuroEyes International Eye Clinic. At Simply Wall St, we found 1 warning sign for EuroEyes International Eye Clinic that deserve your attention before buying any shares.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.